Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers


Chong Kun Dang

Status and phase

Phase 1


Cardiovascular Disease


Drug: CKD-330 Tab. and D086 Tab.
Drug: CKD-333 Tab.

Study type


Funder types




Details and patient eligibility


This study is a randomized, open, single-dose, 3 period partial replicated crossover-design study to investigate the pharmacokinetic profiles and safety of CKD-333 in healthy volunteers.

Full description

To healthy subjects of fifty-one (51), following treatments are administered dosing in each period and wash-out period is a minimum of 14 days.


51 estimated patients




19 to 54 years old


Accepts Healthy Volunteers

Inclusion criteria

Healthy adults over the age of 19 years and under the age of 55 years at the time of screening

Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg

* BMI = Weight(kg)/ Height(m)2

  • Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years
  • Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/bacterial, etc.) and vital signs, ECG etc. performed at screening
  • Individuals who signed an informed consent form and decided to participate in the study after being fully informed of the study prior to participation
  • Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion
  • Individuals with the ability and willingness to participate the entire study period

Exclusion criteria

  • Individuals with a medical evidence or a history of clinically significant hepatobiliary, renal, neurologic, respiratory, digestive, endocrine, blood-oncology, urinary, cardiovascular, musculoskeletal or psychiatric
  • Individuals with a medical history of gastrointestinal disease (e.g., Crohn's disease and ulcer) or gastrectomy (excluding simple appendectomy or herniotomy) that may affect drug absorption

Individuals with the following results at screening test:

  • ALT or AST > 2x the upper limit of the normal range
  • Creatinine > upper limit of the normal range or eGFR with MDRD <60 ml/min/1.73 m2
  • ECG Result, QTc > 450msec
  • CPK > UNL(upper normal limit) x 3.0
  • K > 5.5mEq/l
  • Hct < lower limit of the normal range
  • A history of regular alcohol consumption exceeding 21 units/week within the 3 months(1 unit = 10 g = 12.5 ml) prior to screening or individuals who cannot quit drinking from 48hr prior to the first dose to end of last blooding (1 drink (250 mL) of beer (5%) = 10 g; 1 drink (50 mL) of hard liquor (20%) = 8 g; 1 drink (125 mL) of wine (12%) = 12 g)
  • Individuals who smoked more than 20 cigarettes per day within 6 months prior to screening or cannot quit smoking during hospitalization period
  • Individuals who had been administered investigational product(s) of other clinical study or bioequivalence study within the 6 months prior to the first dose of this study

Following vital signs results at screening

  • Sitting systolic blood pressure ≥ 140 mmHg or < 90 mmHg
  • sitting diastolic blood pressure ≥90 mmHg or <60 mmHg
  • Individuals with a medical history of significant drug abuse within one year prior to the screening or positive for abuse drug in urine test results at screening
  • Individuals taking medication known to significantly induce or inhibit drug metabolizing enzymes within 30days before the first administration of clinical trial drug
  • Individuals who had taken prescription or nonprescription drugs within the 10 days prior to the first dose of investigational product(s)
  • Individuals who donated whole blood within the 2 months, or blood components within 1 month prior to the first dose of the investigational product(s)
  • Individuals with hypersensitivity to investigational products or the investigational products ingredients

Patients or conditions deemed to be at risk for using investigational products

  • Patient with hyperkalemia
  • Patients with hepatopathy
  • Patients with hereditary angioedema, ACE inhibitors or angiotensin 2 receptor antagonists who have a history of angioedema
  • Primary hyperaldosteronism
  • Patients with aortic valve stenosis, mitral (valve) stenosis, hypertrophic obstructive cardiomyopathy
  • Patients with ischemic heart disease, ischemic cardiovascular disease, cerebrovascular disease
  • Patients with Intravascular volume depletion
  • Patients with diabetes or kidney failure
  • Patients with renal artery stenosis
  • Patients with muscle disease
  • Patients with Hypothyroidism
  • Patients with a history of muscle toxicity when using statins or fibrates
  • Patients who have recently had a kidney transplant
  • Patients with history of shock
  • Individuals with hereditary diseases of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption etc.
  • Individuals who drunk grapefruit juice or caffeine more than 5 cup per day within 3 months prior to screening or cannot quit drinking during clinical trials period
  • Individuals who cannot eat standard meal in institution
  • Women who are pregnant or may be pregnant
  • Individuals who were deemed to be inappropriate to participate in the study by the investigator

Trial design

Primary purpose




Interventional model

Crossover Assignment


None (Open label)

51 participants in 3 patient groups

Experimental group
Drug: CKD-333 Tab.
Drug: CKD-330 Tab. and D086 Tab.
Experimental group
Drug: CKD-333 Tab.
Drug: CKD-330 Tab. and D086 Tab.
Experimental group
Drug: CKD-333 Tab.
Drug: CKD-330 Tab. and D086 Tab.

Trial contacts and locations



Data sourced from

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems